Abstract 3324: Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximabKrzysztof Domka, Małgorzata Firczuk, Agata Pastorczak et al.|Cancer Research|2022Cited by 1
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical modelsKrzysztof Domka, Małgorzata Firczuk, Agnieszka Dąbkowska et al.|Haematologica|2024Cited by 1